HQL
abrdn Life Sciences InvestorsMarquee-fund ownership over time
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Millennium Management 2× in & out | Q2 2025 | Q3 2025 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at abrdn Life Sciences Investors. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Dec 18, 2025 — the most recent Form 4 on file — not from today.
- Form 40001104659-25-122394Dec 18, 2025
- Form 40001510281-25-000498Sep 23, 2025
- Form 40001510281-25-000492Sep 19, 2025
- Form 40001510281-25-000488Sep 17, 2025
- Form 40001510281-25-000481Sep 15, 2025
- Form 40001510281-25-000449Sep 4, 2025
- Form 40001510281-25-000436Sep 2, 2025
- Form 40001510281-25-000435Aug 27, 2025
- Form 40001510281-25-000428Aug 25, 2025
- Form 40001510281-25-000325May 22, 2025
- Form 40001510281-25-000315May 19, 2025
- Form 40001510281-25-000308May 15, 2025
- Form 40001510281-25-000291May 12, 2025
- Form 40001510281-25-000287May 8, 2025
- Form 40001510281-25-000226Apr 21, 2025
Fundamentals
XBRL · abrdn Life Sciences InvestorsNot enough XBRL history to plot. abrdn Life Sciences Investorshasn't tagged revenue, net income, EPS, or operating cash flow in the SEC us-gaap taxonomy with at least two fiscal-year periods — typical for SPACs / trust vehicles, pre-revenue biotechs, recent IPOs, and foreign filers reporting under IFRS.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for abrdn Life Sciences Investors — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- DEF 14AProxy statementApr 7, 2026
- DEF 14AProxy statementApr 14, 2025
- SC 13D/AFORM SC 13D/AJun 3, 2024
- SC 13D/AFORM SC 13D/AApr 29, 2024
- DEF 14AProxy statementApr 22, 2024
- SC 13D/AFORM SC 13D/AApr 17, 2024
- SC 13D/AFORM SC 13D/AFeb 7, 2024
- SC 13D/AFORM SC 13D/AJan 12, 2024
- SC 13DFORM SC 13DDec 29, 2023
- 8-KFORM 8-KSep 12, 2023
- DEF 14AProxy statementJul 10, 2023
- DEF 14AProxy statementApr 11, 2023
- SC 13G/AAMENDED SCHEDULE 13GFeb 6, 2023
- DEF 14AProxy statementApr 12, 2022
- SC 13G/AAMENDED SCHEDULE 13GJan 21, 2022
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Millennium Management | Q2 2025 | Q3 2025 | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | Q1 2025 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.